Design, synthesis and biological evaluation of N2,N 4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6] thiatriazine derivatives as HIV-1 NNRTIs

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 22, 2013, Pages 7091-7100

  Chen, Wenmin ^a   Zhan, Peng ^a   De Clercq, Erik ^b   Pannecouque, Christophe ^b   Balzarini, Jan ^b   Jiang, Xin ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Drug design; Heterocycle; HIV; NNRTIs; Pyrrolothiatriazine; Reverse transcriptase; Thienothiadiazine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; N2 (2 FLUOROBENZYL) N4 BENZY 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 BROMOBENZYL) N4 (2 CHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 BROMOBENZYL) N4 (2,4 DICHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 CHLOROBENZYL) N4 (2 CYANOBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 CHLOROBENZYL) N4 (2,4 DICHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 FLUOROBENZYL) N4 (2 BROMOBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 FLUOROBENZYL) N4 (2 CHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 FLUOROBENZYL) N4 (2 CYANOBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 FLUOROBENZYL) N4 (2,4 DICHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 FLUOROBENZYL) N4 (3 CHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 (3 FLUOROBENZYL) N4 CYANOMETHYL 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (2 BROMOBENZYL)BENZYL 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (2 CHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (2 CYANOBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (2,4 DICHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (3 CHLOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (3 CYANOBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (4 FLUOROBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 (4 METHYLBENZYL) 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 ALLYL 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 BENZYL 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 CINNAMYL 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; N2 BENZYL N4 CYANOLMETHYL 1,1,3 TRIOXO 2H,4H PYRROLO[1,2 B][1,2,4,6]THIATRIAZINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; THIATRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; NONHUMAN; STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG DESIGN; HETEROCYCLE; HIV; NNRTIS; PYRROLOTHIATRIAZINE; REVERSE TRANSCRIPTASE; THIENOTHIADIAZINE;

BINDING SITES; CELL LINE; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, TERTIARY; PYRROLES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 84885864446     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.09.009     Document Type: Article

References (39)

1. P. Sendi, A.J. Palmer, A. Gafni, and M. Battegay Pharmacoeconomics 19 2001 709
2. L. Waters, L. John, and M. Nelson Int. J. Clin. Pract. 61 2007 105
3. Z. Zhang, R. Hamatake, and Z. Hong Antiviral Chem. Chemother. 15 2004 121
4. R.L. Murphy, and J. Montaner Expert Opin. Investig. Drugs 5 2008 1183
5. W.W. Freimuth Adv. Exp. Med. Biol. 394 1996 279
6. J.C. Adkins, and S. Noble Drugs 56 1998 1055
7. E. Seminari, A. Castagna, and A. Lazzarin Expert Rev. Anti-Infect. Ther. 6 2008 427
8. W. Schaefer, W.G. Friebe, H. Leinert, A. Mertens, T. Poll, W. Von der Saal, H. Zilch, B. Nuber, and M.L. Ziegler J. Med. Chem. 36 1993 726
9. H. Azijn, I. Tirry, J. Vingerhoets, M.P. de Béthune, G. Kraus, K. Boven, D. Jochmans, E. Van Craenenbroeck, G. Picchio, and L.T. Rimsky Antimicrob. Agents Chemother. 54 2010 718
10. K. Andries, H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, and R. Pauwels Antimicrob. Agents Chemother. 48 2004 4680
11. X. Chen, P. Zhan, D. Li, E. De Clercq, and X. Liu Curr. Med. Chem. 18 2011 359
12. T. Bunupuradah, J. Ananworanich, P. Chetchotisakd, P. Kantipong, S. Jirajariyavej, S. Sirivichayakul, W. Munsakul, W. Prasithsirikul, S. Sungkanuparph, and C. Bowonwattanuwong Antiviral Ther. 16 2011 1113
13. P.P. Fulco, and I.R. McNicholl Pharmacotherapy 29 2009 281
14. M.A. Witvrouw, M.E. Arranz, C. Pannecouque, R. Declercq, H. Jonckheere, J.C. Schmit, A.M. Vandamme, J.A. Diaz, S.T. Ingate, J. Desmyter, R. Esnouf, L. Van Meervelt, S. Vega, J. Balzarini, and E. De Clercq Antimicrob. Agents Chemother. 42 1998 618
15. M.E. Arranz, J.A. DÍaz, S.T. Ingate, M. Witvrouw, C. Pannecouque, J. Balzarini, E. De Clercq, and S. Vega Bioorg. Med. Chem. 7 1999 2811
16. E. Arranz, J.A. Díaz, S.T. Ingate, M. Witvrouw, C. Pannecouque, J. Balzarini, E. De Clercq, and S. Vega J. Med. Chem. 41 1998 4109
17. X.Y. Liu, R.Z. Yan, N.G. Chen, and W.F. Xu Chinese Chem. Lett. 18 2007 137
18. X.Y. Liu, R.Z. Yan, Y. Wang, P. Zhan, E. De Clercq, C. Pannecouque, M. Witvrouw, M.T. Molina, and S. Vega Arch. Pharm. (Weinheim) 341 2008 216
19. X.Y. Liu, N.G. Chen, R.Z. Yan, W.F. Xu, M.T. Molina, and S. Vega ChemInform 2006 37
20. P. Zhan, R.Z. Yan, X.Y. Liu, C. Pannecouque, M. Witvrouw, E. De Clercq, M. Molina, and S. Vega Drug Discovery Ther. 5 2011 279
21. X.Y. Liu, P. Zhan, R.Z. Yan, Y.Q. Lin, J. Li, C. Pannecouque, and E. De Clercq Drug Discovery Ther. 2 2008 25
22. R.K. Verma, V.K. Prajapati, G.K. Verma, D. Chakraborty, S. Sundar, M. Rai, V.K. Dubey, and M.S. Singh ACS Med. Chem. Lett. 3 2012 243
23. R.K. Singh, D. Rai, D. Yadav, A. Bhargava, J. Balzarini, and E. De Clercq Eur. J. Med. Chem. 45 2010 1078
24. Y Tian, D. Rai, P. Zhan, C. Pannecouque, J. Balzarini, E. De Clercq, H. Liu, and X.Y. Liu Eur. J. Med. Chem. 82 2013 384
25. E. Kerns, and L. Di Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization 2008 Academic Press
26. E. Arranz, J.A. Diaz, S.T. Ingate, M. Witvrouw, C. Pannecouque, J. Balzarini, E. De Clercq, and S. Vega J. Med. Chem. 41 1998 4109
27. V. Ravichandran, V. Mourya, and R. Agrawal Arkivoc 14 2007 204
28. D.Y. Li, P. Zhan, E. De Clercq, and X.Y. Liu J. Med. Chem. 55 2012 3595
29. C.E. Mowbray, C. Burt, R. Corbau, S. Gayton, M. Hawes, M. Perros, I. Tran, D.A. Price, F.J. Quinton, and M.D. Selby Bioorg. Med. Chem. Lett. 19 2009 5857
30. T.J. Tucker, J.T. Sisko, R.M. Tynebor, T.M. Williams, P.J. Felock, J.A. Flynn, M.T. Lai, Y. Liang, G. McGaughey, and M. Liu J. Med. Chem. 51 2008 6503
31. O.M. Klibanov, and R.L. Kaczor Curr. Opin. Investig. Drugs 11 2010 237
32. K. Ninomiya, T. Shioiri, and S. Yamada Tetrahedron 30 1974 2151
33. Y.Q. Lin, X.Y. Liu, R.Z. Yan, J. Li, C. Pannecouque, M. Witvrouw, and E. De Clercq Bioorg. Med. Chem. Lett. 16 2008 157
34. J. Ren, J. Milton, K.L. Weaver, S.A. Short, D.I. Stuart, and D.K. Stammers Structure 8 2000 1089
35. C. Pannecouque, D. Daelemans, and E. De Clercq Nat. Protoc. 3 2008 427
36. M. Popovic, M. Sarngadharan, E. Read, and R. Gallo Science 224 1984 497
37. F. Clavel, D. Guetard, F. Brun-Vezinet, S. Chamaret, M. Rey, M. Santos-Ferreira, A. Laurent, C. Dauguet, C. Katlama, C. Rouzioux, D. Klatzmann, J.L. Champalimaud, and L. Montagnier Science 233 1986 343
38. R.K. Rawal, R. Tripathi, S. Katti, C. Pannecouque, and E. De Clercq Bioorg. Med. Chem. 15 2007 1725
39. R.K. Rawal, R. Tripathi, S. Katti, C. Pannecouque, and E. De Clercq Eur. J. Med. Chem. 43 2008 2800